- Modafinil for Wakefulness in the Critical Care Units: A Literature Review and Case Series including
- 2 COVID-19 Patients at a Tertiary Care Saudi Hospital
- 4 Marwa Amer, PharmD, B.S. Pharm, BCPS, BCCCP *
- 5 Critical Care Pharmacy Specialist, Medical and Surgical ICU
- 6 Adjunct Assistant Professor- Alfaisal University- College of Medicine
- 7 Pharmaceutical Care Division, MBC # 11
- 8 King Faisal Specialist Hospital & Research Center
- 9 P. O. Box 3354, Riyadh, 11211

3

13

- 10 Tel: +966114647272, Extension: 48030
- 11 Email address: mamer@kfshrc.edu.sa
- 12 Fax number: +966-11-4424184
- 14 Mohammed Bawazeer MD, FRCSC, FACS
- 15 Trauma & Acute Care Surgery
- 16 Consultant Intensivist
- 17 Medical Director, Surgical Critical Care Unit
- 18 Founder and Head of the Surgical Critical Care Chapter, Saudi Critical Care Society
- 19 Department of Critical Care Medicine (MBC 94)
- 20 King Faisal Specialist Hospital & Research Centre
- 21 Email address: mbawazeer@kfshrc.edu.sa
- 23 Abid Shahzad Butt, MD
- 24 Consultant Intensivist
- 25 Department of Critical Care Medicine (MBC 94)
- 26 King Faisal Specialist Hospital & Research Centre
- 27 Email address: asbutt@kfshrc.edu.sa

Talal I. Dahhan, MD, MMEL, Assistant Professor, Alfaisal University, College of Medicine Consultant, Critical Care and Pulmonary Vascular Diseases Critical Care Fellowship Training Program Director Performance Improvement Director Department of Critical Care Medicine (MBC 94) King Faisal Specialist Hospital & Research Centre Email: tdahhan@kfshrc.edu.sa **Education Lead** Division of Pulmonary, Allergy and Critical Care Medicine Department of Medicine Duke University Durham, NC, United States Email: talal.dahhan@duke.edu Eiad Kseibi, MD **Consultant Intensivist** Department of Critical Care Medicine (MBC 94) King Faisal Specialist Hospital & Research Centre Email address: ekseibi6@kfshrc.edu.sa Mouhamad Ghyath Jamil M.D., FCCP Pulmonary/CCM/sleep Medicine Section Head Sleep Medicine Director Tele-ICU Department of Critical Care Medicine (MBC 94) King Faisal Specialist Hospital & Research Centre Email address: mjamil@kfshrc.edu.sa

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

*Corresponding author at: King Faisal Specialist Hospital & Research Center, Pharmaceutical Care

Division (MBC # 11), PO Box 3354, Riyadh, 11211, Tel: +966114647272 Ext 70836 or 48030

Email address: mamer@kfshrc.edu.sa

57

58

59

Modafinil for Wakefulness in the Critical Care Units: A Case Series including COVID-19 Patients at a **Tertiary Care Saudi Hospital** Marwa Amer a,b*, Mohammed Bawazeer c, Abid Butt , Talal Dahhan bc, Eiad Kseibi c, Mouhamad Ghyath Jamil c ^a Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia ^b College of Medicine, Alfaisal University ^c Department of Critical Care Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Cognitive improvement after critical illness is complex. Neuro-stimulants are used to speed up physical and mental processes through the increase in arousal, and wakefulness. In this case series, we reviewed the literature and described the effect of modafinil for wakefulness in a cohort of adult patients admitted to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020. A total of 8 patients included; 3 admitted to COVID-19, 4 surgical, and 1 transplant ICU. Obstructive sleep apnea was noted in 2 (25%), 2 patients (25 %) had an initial neuroimaging that showed hemorrhagic stroke, and 1 (12.5%) showed ischemic stroke with hemorrhagic transformation. Modafinil 100-200 mg daily was started for a median duration of 4 days and the median initiation time in relation to ICU admission was 11 (IQR 9-17) days. Glasgow coma Scale improvement was noted on 5 patients (62.5%). The median duration of mechanical ventilation was 17.5 (IQR 15-31.75) days, and the median ICU stay was 28.5 (IQR 20.25-48) days. All-cause mortality rate was 25 % at 28 days and 62.5 % at 90 days. Modafinil prevented tracheostomy in 1 COVID-19 patient. No significant adverse drug reactions were documented. In our case series, we described our experience for modafinil use for wakefulness in ICU ventilated patients including COVID-19 patients. Based on our observations, the known effects of modafinil, and its safety profile, it holds the potential to facilitate recovery from cognitive impairment. Larger studies are warranted to fully evaluate its role for this indication.

Keywords: Modafinil, neurostimulant, critical care, COVID-19, mechanical ventilation

Word count: abstract: 250 words, main text: 4210 words, references: 45, keywords: 5

1. Introduction

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Intensive care unit (ICU) patients are susceptible to neurocognitive and musculoskeletal complications because of various factors, such as the nature of critical illness, medications, over-sedation, and pain [1]. Moreover, sleep disruption in ICUs remains an elusive and pervasive problem. The 2018 pain, agitation/sedation, delirium, immobility, and sleep disruption (PADIS) guidelines included a brief overview of risk factors contributing to disrupted sleep quality (e.g., architecture, fragmentation, sleep quality score), quantity (e.g., latency, and duration), or circadian rhythm in ICUs [2,3]. Additionally, clinical experience from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suggests its neuro-invasive potential [4-6]. Approximately 36.4% coronavirus disease 2019 (COVID-19) inpatients in a Wuhan hospital exhibited neurological signs and/or symptoms during infection [7]. Manifestations included delirium, confusion, executive dysfunction, anosmia, stroke, headache, Guillain Barré syndrome (GBS), Miller Fisher syndrome, encephalitis, acute necrotizing encephalopathy, myelitis and CNS demyelinating lesions [7,8]. Moreover, critical illness polyneuropathy and ICUacquired weakness have been observed in 25-46% of ICU patients. Duration of ventilation, corticosteroid administration, multi-organ dysfunction, sepsis, hyperglycemia, and renal replacement therapy have all been correlated with ICU-acquired weakness [9-11]. However, their incidence is unknown in patients with SARS-CoV-2 infection. Case reports of critical-illness polyneuropathy and/or myopathy are rare in patients with SARS-CoV-1 and Middle East respiratory syndrome (MERS-CoV), which can be attributed to the low number of correlation studies between these illnesses and the prolonged ICU stay [12,13].

Early mobilization of these patients has become the standard of care; however, somnolent, fatigued, and depressed patients may not be able or willing to comply and may have a delayed recovery [3]. Neuro-stimulants are used to speed up the physical and mental processes through the increase of dopamine, serotonin, norepinephrine, and acetylcholine. This in turn translates to improved neuro-cognition, enhanced arousal, wakefulness, attention, memory, mental, and motor processing speed [14]. Although, the prescribing trends of neuro-stimulants are yet to be fully elucidated, their use is increasing in traumatic brain injury (TBI) patients

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

especially those with coma, vegetative state (VS), or minimally conscious state (MCS). Neuro-stimulants are sometimes prescribed for off label use, to help in arousal and promote wakefulness in ICUs. The clinical rationale is to facilitate transition from VS, and increase participation in physiotherapy and ambulation, thereby, decreasing ICU-related complications such as deep vein thrombosis (DVT), and ICU-acquired delirium, while facilitating self-expression, accelerating recovery, hastening liberation from the ventilatory support, and decreasing ICU length of stay. Selected neuro-stimulants use in neuro-ICU are summarized at **Table S1** [14-25].

Modafinil is approved by US Food and Drug Administration (FDA) for narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Although the mechanism of action of modafinil remains uncertain, its cognition enhancing properties are attributed to the modulation of glutamate, gamma-aminobutyric acid (GABA) and alpha1B noradrenergic receptors while it has minimal effect on serotonin [26]. Modafinil also offers several advantages over other conventional neuro-stimulants as it does not exhibit the same level of sympathomimetic effects, such as behavioral excitation or rebound hypersomnolence, suggesting that its mechanism of action is distinct. It also has a minimal potential for abuse, and does not appear to disrupt normal sleep architecture. Its favorable safety profile makes it an attractive agent for use in critically ill patients. Side effects include insomnia, anxiety, and cataplexy. At our institution, modafinil is approved for improving wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy and idiopathic hypersomnia, shift work sleep disorder and as an adjunctive therapy for obstructive sleep apnea (OSA)/hypopnea syndrome. Prescribing privilege is restricted to neurologists, psychiatrists, and sleep medicine consultants. The efficacy of modafinil on wakefulness has been studied in TBI and post-stroke patients [17, 27-32] [Table 1]. In ICU setting, a case series by Gajewski and colleagues demonstrated clinical improvement after the start of modafinil therapy in 3 nonintubated ICU patients [31]. A retrospective cohort study by Yoonsun et al evaluated whether modafinil improved cognitive function for ICU patients by promoting wakefulness [32]. A total of 60 patients required ventilatory support at a 336-bed community hospital were included. Modafinil resulted in small, nonsignificant increase in Glasgow Coma Scale (GCS) by 0.34 points after controlling for age, baseline severity of illness, and changes in sedation and analgesia over time (95% CI, -0.34 to 0.73 points; p = 0.0743). There was a reduction in exposure to sedatives and analgesics after modafinil was started, resulting in an increasing trend of GCS over time. No major adverse effects were observed. The authors concluded that modafinil did prove beneficial in promoting wakefulness in ICU patients. Its impact on overall patient outcomes in the ICU remains unclear and needs further investigation. In order to gain insight on modafinil use for wakefulness in ICU, we reviewed the literature, described 8 patients, and provided additional clinical data about COVID-19 cases admitted to the ICU. Our aim to describe the clinical characteristics for patients who received modafinil to promote wakefulness and improve cognition, and describe the median change in GCS before and after modafinil therapy. The author also sought to describe the safety, ICU course, and outcomes including duration of mechanical ventilation, ICU length of stay (LOS), hospital LOS, and all-cause of mortality rate.

2. Methods

2.1 Study design and setting:

This was an observational, retrospective, case series performed at a single tertiary care center King Faisal Specialist Hospital and Research Centre (KFSH & RC), Riyadh, the primary referral center in Saudi Arabia. During the COVID-19 pandemic, ICU units were expanded and approximately ~141 COVID ICU beds were added, in addition to approximately ~45 beds in non-COVID ICU units (medical, surgical, transplant/oncology ICUs). The study was approved by the Research Ethics Committee and Clinical Research Committee. The patient's written consent to publish was taken for each case included in the series. Data were collected and managed using institutional Research Electronic Data Capture (REDCap). The inclusion criteria were 1) ICU patients 18 years and older 2) admitted to COVID and non-COVID units between January 2017 and June 2020 3) ICU stay for at least 48 h, 4) started on modafinil during ICU stay for at least 48 h, and 5) required ventilatory support. Those who did not receive modafinil or received modafinil for indications other than ICU wakefulness were excluded. The CARE (CAse REport) guidelines checklist was followed in describing each case included in this study [33]. The trial registered retrospectively at clinical trial. gov [ClinicalTrials.gov Identifier: NCT04751227]

2.2 Variables and statistical approach:

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

Patient demographic data including ICU admission diagnosis, ICU type, comorbidities, and other ICU support [tracheostomy, renal replacement therapy (RRT), steroids, COVID-19 treatment regimen, and vasopressors] were obtained from the electronic medical record (EMR). The status of ventilator use before and after modafinil administration, modafinil initiation time in relation to ICU admission, dose and duration of treatment were also recorded. Severity of illness was evaluated using Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHEII) scores. The worst value for baseline laboratory tests was chosen. These data were collected within the first 24 h after admission to the ICU. If that data were not available, then data closest to admission were recorded. Work up for decreased level of consciousness (LOC) was recorded including metabolic abnormalities, neuroimaging [brain computed tomography (CT), and magnetic resonance imaging (MRI)], electroencephalogram (EEG), lumbar puncture, and cerebrospinal fluid (CSF) analysis. The findings of nerve conduction studies (NCS), electromyography (EMG), and other complications during ICU stay were documented. The GCS 48 h before and 168 h (7 days) after modafinil therapy, ICU LOS, hospital LOS, discharge disposition, duration of mechanical ventilation, and mortality rate were recorded. We defined responders for GCS change as a 2 points increase from baseline post modafinil initiation up to 7 days. Duration of mechanical ventilation was recorded as the number of calendar days from intubation to extubation or until ICU discharge, or death whichever occurs first. All-cause mortality rate was reported at 28 and 90 days. The documentation in the EMR was reviewed to identify the patients started on antipsychotics and possible adverse drug reactions (ADRs) related to modafinil including nervousness, agitation, delirium, hypersensitivity, and drug rash. Naranjo scale was used to evaluate the causality of ADRs and modafinil therapy [34].

Continuous variables were presented as mean ± standard deviation (SD) or median (interquartile range [IQR]) as appropriate, and categorical variables were presented as number and frequency (%). The changes in GCS was

examined graphically over time. Owing to the retrospective and exploratory nature of this case series, no sample size justification is provided. Instead we wish to report all the patients meeting the inclusion criteria which might be useful to other researchers who may want to combine these results with their own in a meta-analytic approach. Descriptive statistical analysis was conducted using IBM SPSS Statistics, windows version 25.0 (IBM Corp., Armonk, NY).

3. Results

3.1. Patient characteristics

A total of 8 patients who met the inclusion criteria were described in this case series. The demographics and clinical characteristics are summarized in **Table 2**. The median patient age was 76 (IQR 64.75-80.25) years, 7 (87.5%) were men, 3 (37.5%) admitted to COVID ICU, and 5 (62.5%) admitted to non-COVID ICU. Regarding the comorbidities, OSA was noted in 2 (25%), and ischemic stroke in 2 (25%). The median SOFA and APACHE II scores were 9.5 (IQR 7.25-11) and 27.5 (IQR 19.5-33), respectively. The median time from ICU admission to modafinil administration was 11 (IQR 9-17) days. Seven patients (87.5%) started on modafinil 100 mg orally every morning while one patient received 200 mg daily for a median duration of 4 days [IQR 3.25-5]. The main indication for modafinil initiation was decreased LOC and altered mental status that potentially preclude successful extubation or liberation from mechanical ventilation. All patients received vasopressors during the ICU stay, and 5 patients (62.5%) started on RRT for pre-existing chronic kidney disease or acute kidney injury. All COVID-19 patients were treated according to our institution protocol for antivirals and immunomodulatory therapies for possibility of cytokine storm. One patient received 5 days of IVIG as part of COVID-19 regimen (patient #1) and one patient received it for possible GBS (patient #8).

3.2. Follow up and ICU complications

Table 3 illustrates the workup for decreased LOC during the ICU stay prior to modafinil initiation. Two patients (25%) had initial neuroimaging that showed hemorrhagic stroke, and one (12.5%) had ischemic stroke with

hemorrhagic transformation; EEG was performed for 6 (75%) patients and none showed epileptic activity. The cerebrospinal fluid (CSF) analysis was done in 4 patients (50%) and 3 patients showed evidence of nosocomial meningitis that was treated with appropriate antimicrobials [patients # 5-7]. The EMG and NCS were positive in 1 patient (12.5%) for the critical illness myopathy – neuropathy [patient # 8].

Complications arising in the ICU included intra-abdominal infections in 2 (25%) [patients # 4,8], Clostridium difficile infection [patients #2,7], endocarditis [patients # 7], cardiac arrest in 2 (25%) [patients # 6, 8], pulmonary embolism in 1 (12.5%) [patient #2], disseminated intravascular coagulation (DIC) in 1 (12.5%) [patient #2], heparin-induced thrombocytopenia (HIT) in 1 (12.5%) [patient #2], and gastrointestinal bleeding (GIB) and hemorrhagic shock in 3 (37.5%) which required massive transfusion [patients # 2, 4,8]. Antipsychotic drug [quetiapine] was started for 2 patients (25%). No other ADRs were documented.

3.3 Outcomes

modafinil was first administered. An improvement was noted in patients # 1, 3, 4, 5, 6. In patient 8, the GCS slightly increased initially after modafinil administration then remains unchanged after that. Patient # 2 and 7, no improvement was noted in GCS after modafinil therapy. **Table 4** describes the clinical outcomes and patients' disposition. The median ratio of partial pressure of oxygen and fraction of inspired oxygen (PO2/FiO2) prior to modafinil administration was 223.5 (IQR 175.75-265) which changed slightly after administration, to a median of 195 (IQR 170-390). The median duration of mechanical ventilation was 17.5 [IQR 15-31.75] days; 6 patients (75%) were alive after 28 days and 3 (37.5%) were alive after 90 days. The median ICU stay was 28.5 (IQR 20.25-48) days, and the median hospital stay was 36.5 (IQR 26.75-115.25) days. Tracheostomy was done in 5 patients (62.5%) and we were able to avoid it in one COVID-19 patient

who was subsequently liberated from mechanical ventilation and successfully extubated (patient #1).

The median change of GCS 48 h before and 168 h after modafinil therapy is displayed in Fig. 1. Time 0 the time

4. Discussion

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

In our case series, we described our experience with modafinil for wakefulness in the critical care units including COVID-19 patients at a tertiary care hospital. In majority of the cases, nonpharmacologic measures to encourage a healthy sleep cycle were employed prior to modafinil initiation. Moreover, we addressed multiple potential etiologies for altered mental status prior to modafinil initiation including primary CNS process, metabolic derangements, hypoxemia or hypercarbia due to respiratory failure, renal or hepatic dysfunction, nutritional deficiencies (e.g. thiamine) in patients with poor nutritional status, infection and sepsis induced encephalopathy, medication effects [sedation required for prolonged intubation], EEG to rule out nonconvulsive seizure, lumbar puncture if the patient's neurological findings were not explained by above studies, and NCS to rule out neuromuscular disorders that could preclude successful extubation. Although we cannot state with certainty that modafinil was the primary reason for improvement of cognition function, the temporal relationship between starting modafinil and patients' improvement makes it a potential contributing factor. The use of modafinil in a population with neurological findings had been examined before and summarized in table 1 [27-32]. The first trial examined the efficacy of modafinil in treating fatigue and EDS in individuals with TBI [27]. This was a single-center, double-blind, placebo-controlled cross-over trial, where 53 participants were randomly assigned to receive up to 400 mg of modafinil, or placebo. After adjusting for baseline scores and period effects, there were no statistically significant differences between improvements seen with modafinil and placebo on Fatigue Severity Scale (FSS) at wk 4 (-0.5 ± 1.88 ; p = 0.80) or wk 10 (-1.4 ± 2.75 ; p = 0.61). For Epworth Sleepiness Scale (ESS) for daytime sleepiness, average changes were significantly greater with modafinil than placebo at wk 4 (-1.2 ± 0.49 ; p = 0.02) but not at wk 10 (-0.5 ± 0.87 ; p = 0.56). Modafinil was safe and well tolerated, although insomnia was reported significantly more often with modafinil than with placebo (p = 0.03). Another trial in mild to severe TBI patients in ICU used lower dose of modafinil of 100-200 mg or placebo every morning for 6 wk [28]. This prospective, double-blind, randomized, placebo-controlled pilot study was aimed at studying the effect of daily modafinil on post traumatic EDS and fatigue. The EDS improved significantly in

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

patients with TBI receiving modafinil treatment, compared to the placebo group. Modafinil, however, had no impact on posttraumatic fatigue. Clinically relevant side effects were not observed. A systematic review for amantadine and modafinil as neuro-stimulants during post-stroke care identified 12,620 publications including 12 modafinil publications (n = 120 patients) [17, 29, 30]. Modafinil was initiated 170 (17, 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350) mg/day, respectively. The most common indication was fatigue for modafinil (n = 5/12; 42%). Only 1 randomized study analyzing the effect of modafinil (8%; n = 21 patients) on acutely hospitalized or ICU patients, witnessed improvement in neurocognitive function. The authors concluded that modafinil may improve cognitive and functional recovery post-stroke, but higher quality data are needed to confirm this conclusion, especially in the acute care setting. Focusing on ICU setting, Gajewski et al published a case series of 3 non-ventilated patients in thoracic surgery ICU without a prior diagnosis of any sleep disorder and receiving a dose of 200 mg modafinil each morning [31]. The primary outcome was to expedite recovery through early rehabilitation. The 1st case was 77-year-old male with a medical history of small non-cancerous lung cells who was readmitted for respiratory distress requiring intubation, then extubated and continued to require intermittent noninvasive ventilation for dyspnea and he was not participating in physical therapy due to hypersomnolence. He was prescribed 200 mg modafinil every morning for 13 d. At day 2, he was weaned on 3-L nasal cannula and made advances in rehabilitation. The 2nd case was a 67-year-old male with a medical history of esophageal cancer. He was admitted to ICU for management of pneumonia and sepsis and received washouts for gastro-pleural fistula. After his initial surgery, he was noted to be extremely fatigued and expressing wishes to withdraw care. Modafinil 200 mg every morning was started and on day 2, the patient was more engaged in his care. No side effects were noted throughout the 8 days course. The 3rd case was a 70-year-old male with a medical history of esophageal cancer was admitted to the ICU for respiratory failure which was improved and eventually extubated. His rehabilitative status was complicated by his overall lack of energy, and his waxing and waning mental status. Modafinil was started at a dose of 100 -200 mg. At day 6, the patient did not need his home lorazepam 1.5 mg at night and he engaged

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

more in his care. The author concluded that modafinil was beneficial in the ICU owing to its effects on improving sleep efficiency, adjusting circadian sleep-cycle disruption, and decreasing EDS which subsequently reduce delirium, improve day-time cognition, improve wakefulness, and facilitate engagement with physical therapy and rehab. Compared to those findings, our observations suggested that modafinil improves cognition and increases GCS in 5 (62.5%) patients in our series, suggesting it might be reasonable for promoting wakefulness in ICU patients especially in mechanically ventilated patients which have not been described in the prior case series [31]. Moreover, we included more diverse cohort from transplant, surgical, and COVID-19 ICUs which had not been reported in the prior literature [31,32]. Mechanically ventilated COVID-19 patients may require higher doses of opioids and sedatives to mitigate ventilator-induced lung injury, and prevent self-extubation. Deep levels of sedation may also require prior to initiation of neuromuscular blocking agents (NMB) in moderate-tosevere acute respiratory distress syndrome (ARDS) [35]. All these factors could potentially delay the recovery of neurocognitive function and increase risks of ICU acquired weakness particularly when corticosteroids are used with aminosteroidal NMB [36]. However, clinicians should also be cognizant that COVID-19 patients are predominately presented with hyperactive delirium, and agitation due to multiple factors including direct virus invasion to CNS, prolonged mechanical ventilation, social isolation, and restricted family visitation [37]. Therefore, comprehensive assessment is warranted to identify those who might benefit from modafinil as wakefulness agent prior to initiation of therapy. Moreover, the most common dose of modafinil that was used in our series 100 mg oral once every morning with a median duration of 4 days and was fairly tolerated. Based on published data, the usual dose of modafinil is 100-400 mg (starting dose 100-200 mg oral daily with a lower dose recommended for patients with cardiovascular diseases and liver cirrhosis) [31, 32]. Therefore, a less ideal response in term of GCS improvement was observed in patients # 2, 7, and 8 which might be due to inadequate modafinil dose. Hence, a higher dose might be reasonable to use in these situations. Regarding the safety and ADRs, we used the Naranjo scale for assessment of causality and a score of 0 to -1 indicated a doubtful causality of ADRs and modafinil therapy in our series [34]. The ICU complications were most likely attributed to underlying comorbidities.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

Interestingly, modafinil prevented tracheostomy in one patient with COVID-19 (case 1) who was then successfully extubated. A previous report showed that patients with COVID 19 who required prolonged mechanical ventilation had a high mortality rate. Therefore, tracheostomy might be considered when prolonged mechanical ventilation is anticipated [38]. On the other hand, studies showed that tracheostomy carries significant risk of viral transmission to the healthcare workers [39]. Hence, preventing tracheostomy provided advantages including shortening duration of critical care resource use (ventilators) and ICU length of stay during COVID-19 outbreak, and minimizing aerosolization risks associated with this procedure for healthcare workers. Furthermore, 2 patients (case # 5, and 7) has a neuroimaging that showed hemorrhagic stroke, 1 patient (case #6) showed ischemic stroke with hemorrhagic transformation, a population which had not been assessed for modafinil treatment in the prior literature [17, 27-32]. Moreover, 2 (25 %) of the patients (case #4, and 5) had a history of OSA. We speculated that the observed improvements in cognition and GCS of these patients possibly were related to enhanced nocturnal sleep based on the drug mechanism of action; however, further evaluation is still needed. The 28 d all-cause mortality rate in our series was 2 (25 %) and 90 d all-cause mortality rate was 5 (62.5%) and this is possibly expected as we are a tertiary care hospital. Therefore, it is likely that our patients were sicker, as the APACHEII and SOFA scores suggest that these data were derived from a cohort of critically ill patients. This is comparable to the mortality rate in patients admitted to the ICU with severe sepsis and shock [40-42]. Our study limitations were small sample size, single institution experience, retrospective and observational in nature, and lack of a control group which precludes causal interpretations. Similar to other observational studies, our findings can be biased by confounding from unmeasured factors that influence cognitive function and recovery such as the effect of physiotherapy and rehabilitation. It is also plausible that the increasing trend in GCS over time was largely owing to the result of reduced exposure to other sedatives and analgesics and spontaneous recovery. Moreover, patient-family interaction has a great impact in patient recovery as shown in the recent report [43, 44]. In our series, the intensivist on service had the patient described in case 1 interact with the patient's family through video calling, which likely uplifted his spirit and played a potential role in his

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

recovery. Additionally, the small sample size prohibited us from performing statistical analysis to assess and adjust for confounders or perform analysis of what factors might be associated with response or lack thereof. This may have led to an overestimation or underestimation of modafinil effect for wakefulness in the critical care unit [45]. As is always the case with observation type study, association does not prove causality, but there are reasonable data showing that modafinil might have potential benefits when administered to certain critically ill patients especially those who appear hypoactive, lethargic, and depressed and particularly when conservative treatment has failed, which provides biological plausibility [17, 27-32]. Its daily cost is insignificant compared with the high cost of an extended ICU stay although it is difficult to conclude from our experience that patients' length of ICU stay was shortened. Nonetheless, we felt that it is important to report our experience to help rationalize and understand the role of neurostimulants to promote arousal and wakefulness in the ICU which subsequently facilitate self-expression, accelerate recovery, increase participation in physiotherapy and ambulation, hastening liberation from the ventilatory support, and decrease ICU-related complications such as DVT, and ICU-acquired delirium. Based on our observations of these patients, the known effects of modafinil, its safety profile, and the published experiences of others, we believe that modafinil might has potential benefits and that the consequences of delayed patient recovery and a prolonged ICU stay may outweigh the risks of potential modafinil side effects. Although we cannot state with certainty that modafinil improves cognition function and GCS in our series, it seems that the timing of drug administration in concert with the putative benefits of the medication makes it a plausible conclusion. There are many unanswered questions that we believe would be a good starting point for a larger randomized controlled trial to substantiate the ideal time of modafinil initiation, identify the population that most likely benefit from therapy, define the optimal drug dose and duration, and identify the role of a combination therapy and its impact on clinical outcomes. Future studies with appropriate sample size, adequate power are needed to better describe its role in the ICU patients post hemorrhagic stroke. Additionally, the impact of modafinil therapy on overall ICU outcomes, such as mortality, duration of mechanical ventilation, and ICU length of stay

should be evaluated in future prospective studies. Lastly, further studies are needed to provide more insights and understand modafinil use in critically ill COVID-19 patients. However, in this pandemic setting, evidence of some physiological safety and possible benefit might be considered for hypothesis generation, as shown in our series.

5. Conclusion

Cognitive improvement after critical illness is complex. In our case series, we reviewed the literature and described our center's experience for modafinil use for wakefulness in the ICU ventilated patients including COVID-19 patients. Based on our observations of these patients, the known effects of modafinil, and its safety profile, we believe that modafinil might has potential benefits when administered to certain critically ill patients especially those who appear hypoactive, and lethargic after comprehensive assessment of potential etiologies for altered mental status. Though our observations are intriguing, they result from uncontrolled, retrospective chart review and confounding bias is likely which preclude definitive statements. Nevertheless, this initial experience is promising and may provide preliminary evidence and hypothesis warrant to be assessed in randomized controlled trials.

Tables and Figure

- **Table 1:** Trials on modafinil use in neuro and ICU population
- **Table 2:** Demographics and baseline characteristics
- **Table 3:** Workup for decreased level of consciousness (LOC) and complications during ICU stay
- **Table 4:** Clinical outcome and patients disposition
- Figure 1: Trend of Glasgow Coma Scale (GCS) over time before and after modafinil

Figure Legend: The graphs present the median change of GCS 48 h before and 168 h (7 days) after modafinil therapy. The GCS ranges from 3 to 15, with higher scores indicating a higher level of consciousness. Time 0 the time modafinil was first administered. Improvement was noted on patient # 1, 3, 4, 5, 6. No improvement was noted for patient # 2, 7. Patient # 8 received modafinil twice: first trial was 100 mg oral every morning for 5 days [patient 8 a] and the second trial was of 100 mg oral every

morning for 6 days [patient 8 b]. In both scenarios, the GCS slightly increased initially after modafinil administration then remains unchanged after that.

Figure Abbreviation: GCS: Glasgow Coma Scale

Supplemental Digital Content

Table S1 Selected neuro-stimulants use in neuro-ICU

Acknowledgment

We thank the ICU physicians, ICU nurses, ICU respiratory therapists, ICU physiotherapists, ICU satellite pharmacists, and ICU clinical pharmacists of KFSH&RC for their efforts to save the life of ICU patients and their braveness in fighting against COVID-19 pandemic. We appreciate pharmacy automation team effort and their help to identify the ICU cases for our series [Maher Mominah, and Rania Al-Jaber]. We are also thankful for Hala Khalil, PhD, Department of Biostatistics, Epidemiology and Scientific Computing for providing help in biostatistical part of manuscript.

Authors contribution

MA: proposed the study, led the manuscript writing and did the data collection. MG: proposed the idea, gave approval for modafinil as a sleep medicine consultant, reviewed and edited the manuscript. MA, MB, AB, MG made substantial contributions to the concept and design of this project and has further participated in the analysis and interpretation of the data. TD, EK: reviewed and edited the final version of the manuscript. All authors participated in the care of the patients, revised the manuscript for important intellectual content and approved the final version to be published. We confirmed that the authorship followed the uniform requirements for manuscripts submitted to biomedical journals.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or notfor-profit sectors. **Declarations of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Availability of data and material The datasets used and analyzed during the current report are available from the corresponding author on reasonable request.

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

List of Abbreviation: acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), adverse drug reactions (ADRs), cerebrospinal fluid (CSF), computed tomography (CT), coronavirus disease 2019 (COVID-19), central nervous system (CNS), continuous renal replacement therapies (CRRT), deep vein thrombosis (DVT), diabetes type 2 (DM-2), disseminated intravascular coagulation (DIC), do-not-resuscitate (DNR), end-stage renal disease (ESRD), external ventricular drain (EVD), electroencephalogram (EEG), electromyogram and nerve conduction study (EMG and NCS), emergency department (ED), epworth sleepiness scale (ESS), excessive daytime sleepiness (EDS), fatigue severity scale (FSS), Glasgow Coma Scale (GCS), Guillian Barré syndrome (GBS), gammaaminobutyric acid (GABA), gastrointestinal bleeding (GIB), heparin-induced thrombocytopenia (HIT), hepatitis C virus (HCV), heart failure with preserved ejection fraction (HFpEF), hemodialysis (HD), intensive care unit (ICU), intravenous immunoglobulin (IVIG), intracranial bleeding (ICH), intraventricular hemorrhage (IVH), King Faisal Specialist Hospital and Research Centre (KFSH&RC), level of consciousness (LOC), lumbar puncture (LP), Middle East respiratory syndrome (MERS), myocardial infarction (MI), minimally conscious state (MCS), middle cerebral artery (MCA), magnetic resonance imaging (MRI), neuromuscular blocking agents (NMB), operating room (OR), Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS), renal replacement therapy (RRT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), vegetative state (VS).

References

- 416 1. Wijdicks EFM. Metabolic encephalopathy: behind the name. *Neurocrit Care*. 2018;29:385–7.
- 417 doi: 10.1007/s12028-017-0497-1.
- 418 2. Elías MN, Munro CL, Liang Z, Calero K, Ji M. Sleep and Intensive Care Unit-Acquired Weakness in
- 419 Critically III Older Adults. Dimens Crit Care Nurs. 2019 Jan/Feb;38(1):20-28. doi:
- 420 10.1097/DCC.00000000000335.
- 421 3. Devlin JW, Skrobik Y, Gélinas C et al. Clinical practice guidelines for the prevention and management
- of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit
- 423 Care Med. 2018;46:e825-73. DOI: 10.1097/CCM.0000000000003299
- 424 4. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. *J Exp*
- 425 *Med.* 2005;202:415–24. DOI: 10.1084/jem.20050828
- 426 5. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical,
- radiological and laboratory findings. *Brain*. 2020;8. DOI: 10.1093/brain/awaa240
- 428 6. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus
- 429 Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690.
- 430 doi:10.1001/jamaneurol.2020.1127
- 431 7. Helms J, Kremer S, Merdji H et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J
- 432 *Med.* 2020 June 4;382:2268–70. DOI: 10.1056/NEJMc2008597.
- 433 8. Toscano G, Palmerini F, Ravaglia S et al. Guillain-Barré syndrome associated with SARS-CoV-2. N
- 434 Engl J Med. 2020 June 25;382:2574–6. DOI: 10.1056/NEJMc2009191. Epub April 17 2020.
- 435 9. De Jonghe B, Sharshar T, Lefaucheur JP et al. Paresis acquired in the intensive care unit: a prospective
- 436 multicenter study. *JAMA*. 2002;288:2859–67. doi: 10.1001/jama.288.22.2859.
- 437 10. Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, Needham DM. Neuromuscular
- dysfunction acquired in critical illness: a systematic review. Intensive Care Med. 2007 Nov;33(11):1876-
- 439 91. doi: 10.1007/s00134-007-0772-2.

440 11. Tsai L, Hsieh S, Chao C, et al. Neuromuscular Disorders in Severe Acute Respiratory Syndrome. Arch 441 Neurol. 2004;61(11):1669-1673. doi:10.1001/archneur.61.11.1669. 442 12. Shirah B. Neurological Middle Algahtani H, Subahi A, complications of East 443 respiratory syndrome coronavirus: A report of two cases and review of the literature. Case Rep Neurol 444 Med. 2016;2016:3502683. doi: 10.1155/2016/3502683 445 13. Bleck TP. How critical illness affects the brain ...and vice versa. Crit Care Med. 2018;46:465-70. doi: 446 10.1097/CCM.0000000000002944. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic 447 14. brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma 448 Rehabil. 2002;17:300-13. doi: 10.1097/00001199-200208000-00004 449 450 15. Saniova B, Drobny M, Kneslova L, Minarik M. The outcome of patients with severe head injuries 451 treated with amantadine sulphate. J Neural Transm. 2004;111:511-4. doi: 10.1007/s00702-004-0112-452 4. 453 16. Giacino JT, Whyte J, Bagiella E et al. Placebo-controlled trial of amantadine for severe traumatic brain 454 injury. N Engl J Med. 2012;366:819–26. doi: 10.1056/NEJMoa1102609 17. Gagnon DJ, Leclerc AM, Riker RR et al. Amantadine and modafinil as neurostimulants during post-455 stroke care: A systematic review. Neurocrit Care. 2020;12:020-00977. doi: 10.1007/s12028-020-456 457 00977-5 458 18. Chollet F, Tardy J, Albucher JF et al. Fluoxetine for motor recovery after acute ischaemic stroke 459 (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123-30. doi: 10.1016/S1474-460 4422(10)70314-8. 461 19. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (Focus): a

pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393:265-74. doi: 10.1016/S0140-

462

463

6736(18)32823-X

- 464 20. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:651–660. 465 doi: 10.1016/S1474-4422(20)30207-6 466 467 21. Moein H, Khalili HA, Keramatian K. Effect of methylphenidate on ICU and hospital length of stay in 468 patients with severe and moderate traumatic brain injury. Clin Neurol Neurosurg. 2006;108:539–42. 469 DOI: 10.1016/j.clineuro.2005.09.003 Johansson B, Wentzel AP, Andréll P, Odenstedt J, Mannheimer C, Rönnbäck L. Evaluation of dosage, 470 22. 471 safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental 472 fatigue and pain. Brain Inj. 2014;28:304-10. doi: 10.3109/02699052.2013.865267 23. Johansson B, Wentzel AP, Andréll P, Mannheimer C, Rönnbäck L. Methylphenidate reduces mental 473 474 fatigue and improves processing speed in persons suffered a traumatic brain injury. Brain 475 *Inj.* 2015;29:758–65. DOI: 10.3109/02699052.2015.1004747 Martinsson L, Hårdemark H, Eksborg S. Amphetamines for improving recovery after stroke. Cochrane 476 24. 477 Database Syst Rev. 2007;24:CD002090. doi: 10.1002/14651858.CD002090.pub2. 478 25. Schuster C, Maunz G, Lutz K, Kischka U, Sturzenegger R, Ettlin T. Dexamphetamine improves upper 479 extremity outcome during rehabilitation after stroke: a pilot randomized controlled trial. Neurorehabil 480 Neural Repair. 2011;25:749-55. doi: 10.1177/1545968311405674. 481 26. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67:554-66. doi: 10.4088/jcp.v67n0406. 482 Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and 483 27. 484 excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma 485 Rehabil. 2008;23:52-63. doi: 10.1097/01.HTR.0000308721.77911.ea.
- 486 28. Kaiser PR, Valko PO, Werth E, et al. Modafinil ameliorates excessive daytime sleepiness after traumatic 487 brain injury. *Neurology*. 2010;75:1780–5. doi: 10.1212/WNL.0b013e3181fd62a2.

488 29. Poulsen MB, Damgaard B, Zerahn B, Overgaard K, Rasmussen RS. Modafinil May Alleviate Po

- 489 Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial. Stroke. 2015 Dec;46(12):3470-7.
- 490 doi: 10.1161/STROKEAHA.115.010860
- 491 30. Bivard A, Lillicrap T, Krishnamurthy V. MIDAS (modafinil in debilitating fatigue after stroke):
- 492 A randomized, double-blind, placebo-controlled, cross-over trial. *Stroke*. 2017;48:1293–8. doi:
- 493 10.1161/STROKEAHA.116.016293.
- 494 31. Gajewski M, Weinhouse G. The use of modafinil in the Intensive Care Unit. J Intensive Care
- 495 *Med.* 2016;31:142–5. doi: 10.1177/0885066615571899.
- 496 32. Mo Y, Thomas MC, Miano TA. Effect of modafinil on cognitive function in Intensive Care Unit patients:
- 497 A retrospective cohort study. *J Clin Pharmacol*. 2018;58:152–7. doi: 10.1002/jcph.1002
- 498 33. Gagnier et al.: The CARE guidelines: consensus-based clinical case reporting guideline development.
- 499 Journal of Medical Case Reports 2013 7:223. doi: 10.7453/gahmj.2013.008
- 500 34. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug
- reactions. Clin Pharacol Ther. 1981;30:239–45. doi: 10.1038/clpt.1981.154.
- 502 35. Ammar MA, Sacha GL, Welch SC, et al. Sedation, Analgesia, and Paralysis in COVID-19 Patients in the
- 503 Setting of Drug Shortages. J Intensive Care Med. 2020 Aug 26:885066620951426. doi:
- 504 10.1177/0885066620951426.
- 505 36. Mefford B, Donaldson JC, Bissell BD. To Block or Not: Updates in Neuromuscular Blockade in Acute
- Respiratory Distress Syndrome. Ann Pharmacother. 2020 Sep;54(9):899-906. doi:
- 507 10.1177/1060028020910132.
- 508 37. Kotfis, K., Williams Roberson, S., Wilson, J.E. et al. COVID-19: ICU delirium management during SARS-
- 509 CoV-2 pandemic. Crit Care 24, 176 (2020). doi: 10.1186/s13054-020-02882-x
- 510 38. Auld S, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with
- 511 Coronavirus Disease 2019. Crit Care Med. 2020 May 26 . doi: 10.1097/CCM.000000000004457 .

512	39.	Shiba T, Ghazizadeh S, Chhetri D, St John M, Long J. Tracheostomy considerations during the COVID-
513		19 pandemic. OTO Open. 2020;4:2473974X20922528. DOI: 10.1177/2473974X20922528
514	40.	Mohamed AKS, Mehta AA, James P. Predictors of mortality of severe sepsis among adult patients in
515		the medical Intensive Care Unit. Lung India. 2017;34:330–5. DOI: 10.4103/lungindia.lungindia_54_16
516	41.	Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess deaths from COVID-19 and
517		other causes, March-April 2020. JAMA. 2020. DOI: 10.1001/jama.2020.11787
518	42.	Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic
519		review of the emerging literature. Crit Care. 2020;24:285. doi: 10.1186/s13054-020-03006-1
520	43.	Devlin JW, O'Neal HR Jr, Thomas C, et al. Strategies to optimize ICU liberation (A to F)
521		bundle performance in critically ill adults with coronavirus Disease 2019. Critical Care
522		Explorations. 2020 June 12;2:e0139. DOI: 10.1097/CCE.0000000000139.
523	44.	Pun BT, Balas MC, Barnes-Daly MA, et al. Caring for critically ill patients with the ABCDEF bundle:
524		results of the ICU Liberation Collaborative in over 15,000 adults. Crit Care Med. 2019;47:3–14. DOI:
525		10.1097/CCM.00000000003482
526	45.	Fanaroff AC, Califf RM, Harrington RA. Randomized Trials Versus Common Sense and Clinical Observation:
527	.5.	JACC Review Topic of the Week. <i>J Am Coll Cardiol</i> . 2020;76:580–589. doi:10.1016/j.jacc.2020.05.069
J21		JACC NEVIEW TOPIC OF THE WEEK. J AITI COIL CULUIOI. 2020, 10.300-303. UOI.10.1010/J.Jacc.2020.03.003
528		

Figure 1: Trend of Glasgow Coma Scale (GCS) over time before and after modafinil




Table 1: Trials on modafinil use in neuro and ICU population

Table 1. Thats on modalitin use in neuro and reo population				
Study	Patient population	Outcomes	Regimen	Results
Jha <i>et al</i> . Double – blind placebo controlled cross over (2008)/ n= 53 [27]	Moderate – Severe TBI	Fatigue Severity Scale (FSS) and daytime sleepiness (Epworth Sleepiness Scale, ESS) at wk 4 and wk 10	Modafinil titrated to 400 mg/day or placebo for 10 wk	Clear benefit from modafinil was not seen at wk 4 or wk 10
Kaiser <i>et al</i> . Prospective, double blind, randomized, placebo controlled (2010)/ n= 20 [28]	Mild to severe TBI patients in ICU	FSS and ESS at baseline and after 6 wk	Modafinil 100-200 mg or placebo every morning for 6 wk	Modafinil improved excessive daytime sleepiness but not fatigue
Poulsen <i>et al</i> . Double blinded, placebo controlled (2015)/ n= 41 [29]	Ischemic stroke with modified Rankin Scale score of ≤3 before admission	Fatigue at 90 d (multidimensional fatigue inventory)	Modafinil 400 daily or placebo for 90 d and started 1-14 d post stroke	No significant differences between the 2 groups
Bivard A <i>et al</i> . Randomized, double blind, placebo- controlled, crossover MIDAS trial (2017)/ n = 36 [30]	Ischemic stroke with multi-dimensional fatigue inventory score of ≥60	Fatigue (multidimensional fatigue inventory)	Modafinil 200 mg daily or placebo for 6 wk, 1 wk washout, started at least 3 mo post stroke	Modafinil decreased fatigue
Gagnon DJ et al. systematic review for amantadine and modafinil (2020)/ n= 120 [17]	Post - stroke	Cognitive and functional recovery	Modafinil 170 days post-stroke. Daily doses of 100- 200 mg/day	Modafinil may improve cognitive and functional recovery post-stroke, but higher quality data are needed
Gajewski <i>et al.</i> Case series (2015) / n=3 [31]	Non-ventilated patients in thoracic surgery ICU	Increase patient wakefulness, and enable a more restful sleep during the night	200 mg in the first 2 cases and 100 mg in the 3rd case increased later to 200 mg	All 3 pts more engaged in their care and made advances in rehabilitation . No side effect was observed
Yoonsun et al. retrospective cohort study (2017)/ n= 60 [32]	60 ICU patients with ventilatory support [medical, surgical, neuro ICU]	Requirements of opioids and sedatives, lowest and average scores of the GCS and SAS during 48 h before and after modafinil	median modafinil dose 170 mg with median duration of 9 d	Modafinil resulted in small, nonsignificant increase in GCS by 0.34 points after controlling for age, baseline severity of illness, and changes in sedation and analgesia over time (95% CI, -0.34 to 0.73 points; p = 0.0743)

Study	Patient population	Outcomes	Regimen	Results
Current study, observational case series (2020) / n= 8	8 ICU intubated patients [3 COVID-19 ICU, 4 surgical ICU, 1 transplant ICU]	Clinical characteristics, median change in GCS 48 h before and 168 h after modafinil	Modafinil 100-200 mg median duration 4 days	GCS improvement was noted on 5 patients (62.5%)

Table Footnote

Abbreviation: EDS: excessive daytime sleepiness, GCS: Glasgow Coma Scale, ICU: intensive care unit,

MIDAS: Modafinil in Debilitating Fatigue After Stroke, n: sample size, SAS: Riker Sedation-Agitation Scale,

TBI: traumatic brain injury

Table 2: Demographics and baseline characteristics

Patient characteristics	Value
Sex , male (n, %)	7 (87.5)
Age	
Median (IQR), years	76 (64.75-80.25)
Comorbidities (n, %)	
Heart failure	2 (25)
Atrial fibrillation	4 (50)
Hypertension	6 (75)
Diabetes type 2	5 (62.5)
Ischemic stroke	2 (25)
Seizure	1 (12.5)
Dyslipidemia	2 (25)
Chronic kidney disease	2 (25)
Below knee amputation	1 (12.5)
Hepatitis C virus Obstructive sleep apnea	1 (12.5) 2 (25)
Osteoarthritis	1 (12.5)
Bilateral knee replacement	1 (12.5)
Solid organ transplant (kidney)	1 (12.5)
Liver cirrhosis secondary to NASH	1 (12.5)
Rheumatic heart disease	1 (12.5)
Mechanical mitral valve replacement	1 (12.5)
Type of ICU (n, %)	
COVID-19 ICU	3 (37.5)
Surgical ICU	4 (50)*
Transplant ICU	1 (12.5)
Diagnosis during ICU admission (n, %)	
Hypoxemic respiratory failure secondary COVID-19	1 (12.5)
Transferred from outside hospital with COVID-19 pneumonitis †	2 (25)
OR post exploratory laparotomy and small bowel resection	1 (12.5)
Surgical evacuation of intraventricular bleeding	1 (12.5)
Interventional thrombectomy for left internal carotid artery thrombosis	1 (12.5)
Right frontal EVD insertion Intracranial bleed	1 (12.5)
Post living related liver transplant	1 (12.5)
SOFA score	0.5 /7.35 44)
Median (IQR)	9.5 (7.25-11)
APACHE II score	27 5 /40 5 22\
Median (IQR)	27.5 (19.5 -33)
Modafinil dose (n, %)	

Patient characteristics	Value
100 mg oral every morning	7 (87.5)
100 mg oral every 12 hours	1 (12.5)
Modafinil duration	
Median (IQR), days	4 (3.25-5)
Modafinil start time in relation to ICU admission (days)	
Median (IQR), days	11 (9-17)
ICU medications and support (n, %)	
Vasopressors	8 (100)
Steroids	7 (87.5)
Renal replacement therapy (RRT)	5 (62.5)
Tocilizumab	1 (12.5)
Azithromycin	3 (37.5)
Hydroxychloroquine	3 (37.5)
Ribavirin	1 (12.5)
Intravenous immunoglobulin (IVIG)	2 (25)
Convalescent plasma	1 (12.5)
Antibiotics per infectious diseases team	5 (62.5)
Anti-epileptics	3 (37.5)
Nimodipine	1 (12.5)
Immunosuppressants	1 (12.5)
Antipsychotic: quetiapine	2 (25)

Table Footnote

† One patient transferred intubated from outside hospital (patient #2), and one transferred on nasal cannula from outside hospital and intubated at our institution (patient #3)

Abbreviation: APACHE: Acute Physiology and Chronic Health Evaluation, COVID-19: Coronavirus disease, EVD: External Ventricular Drain, NASH: Nonalcoholic steatohepatitis, SOFA: Sequential Organ Failure Assessment

^{* 3} patients (37.5 %) were neurosurgical ICU

Table 3: workup for decreased level of consciousness (LOC) and complications during ICU stay

NA/auluus aust aansultaattaus	Walter
Workup and complications	Value
Metabolic abnormalities prior to	
modafinil starts (n, %)	
AKI	4 (50)
ALF	6 (75)
Hypoglycemia	0 (0)
Initial neuroimaging (n, %)	
CT Brain	6 (75)
MRI brain	2 (25)
Time of initial neuroimaging (n. 0/)	
Time of initial neuroimaging (n, %)	2 (27.5)
Day 1 of ICU admission	3 (37.5)
Day 2 of ICU admission	1 (12.5)
Day 4 of ICU admission	1 (12.5)
Day 5 of ICU admission	1 (12.5)
Other *	3 (37.5)
Initial neuroimaging findings	Patient # 2,3,4: no evidence of acute intracranial insult
mittal fledfollflaging findings	Patient #1: Stigmata of age related severe microangiopathic ischemic changes with
	multiple scattered areas of encephalomalacia
	Patient #5: Post-surgical changes from recent evacuation of the right frontal
	hematoma with extensive IVH and active hydrocephalus
	Patient #6: Status post mechanical thrombectomy with interval development of left
	basal ganglia and intraventricular hemorrhage. Interval progression of the left MCA
	territory acute infarction with diffuse hypo attenuation and cytotoxic edema
	Patient #7: evidence of SAH within supratentorial and infratentorial regions with IVH
	associated with slight interval progression of hydrocephalus
	Patient #8: Small left frontal and right occipital acute/subacute infarcts with
	associated minimal punctate blood staining in the left frontal lobe. New small
	bilateral parietal microhemorrhages
Deposted neuroinessis = (= 0/)	
Repeated neuroimaging (n, %)	4 (50)
None	4 (50)
CT brain	3 (37.5)
MRI brain	0
Time of repeated neuroimaging (n,	
%)	
Day 3 of ICU admission	1 (12.5)
Day 5 of ICU admission	1 (12.5)
Day 3 of ICU admission	1 (12.3) 2 (25)

Repeated Neuroimaging findings

Day 7 of ICU admission

Other \$

Patient #2: No CT evidence of acute intracranial abnormality

2 (25)

2 (25)

Workup and complications

Value

Patient #5: Status post right frontal craniotomy for evacuation of right frontal IPH and IVH with the placement of two drains. Interval evolution of right frontal IPH and IVH and slight decrease in ventricular dilatation.

Patient #6: post-surgical changes from decompressive craniectomy and evacuation of basal ganglia hematoma with large left ACA/MCA territory infarction. Interval worsening of the rightward midline shift of 1.1 cm. Interval placement of the left frontal EVD with interval improvement in the size of the right lateral ventricle.

Patient #7 Day 8: Several probable embolic infarcts in the right centrum ovale and corpus callosum, mild interval improvement of the SAH, no significant interval change of the IVH and ventricular dilatation.

Patient #7 Day 13: Status post right frontal burr hole for insertion of EVD. No change in ventricular size. Signs of subacute IVH with no evolution of previously noted hemorrhage layering along occipital horns

Patient #7 Day 25: Interval removal of right EVD, interval decrease of the IVH, with improvement of hydrocephalus, no new hemorrhage or acute abnormality

EEG (n, %)	6 (75)
EEG finding of seizure activity (n, %)	0 (0)
Lumbar puncture and CSF analysis (n, %)	4 (50)
EMG and NCS (n, %)	1 (12.5)
EMG and NCS finding: critical illness myopathy – neuropathy (n, %)	1 (12.5)
Complication during ICU stay (n, %)	
Nosocomial meningitis	3 (37.5)
Intra-abdominal infections	2 (25)
Other infections	5 (62.5)
Cardiac arrest	2 (25)
Pulmonary embolism	1 (12.5)
DIC	1 (12.5)
HIT	1 (12.5)
GIB	3 (37.5)
Hemorrhagic shock	1 (12.5)

Table Footnote

\$ Others: Day 11 (patient #5), Day 8, day 13 and day 25 (patient #7) of ICU admission

^{*} Others: Day 15 (patient #1), day 8 (patient #3), 4 months (patient #8) of ICU admission

Abbreviation: AKI: acute kidney injury, ALF: acute liver failure, ACA: anterior cerebral artery, CSF: cerebrospinal fluid, CT: computed tomography, DIC: disseminated intravascular coagulation, EEG: electroencephalogram, EVD: external ventricular drain, EMG and NCS: electromyogram and nerve conduction study, GIB: gastrointestinal bleeding, HIT: heparin-Induced thrombocytopenia, IPH: intraparenchymal hemorrhage, IVH: intraventricular hemorrhage, MRI: magnetic resonance imaging, MCA: middle cerebral artery, SAH: subarachnoid hemorrhage

Table 4: Clinical outcomes and patients disposition

Clinical outcome	Value		
MV setting prior to start Modafinil			
FIO2			
Median (IQR)	0.33 (0.29-0.39)		
PEEP			
Median (IQR), cmH2O	8 (5.25-9.5)		
PaO2/ Fio2			
Median (IQR)	223.5 (175.75-265)		
MV mode (n, %)			
PCV	2 (25)		
PS	2 (25)		
PRVC	2 (25)		
Alternating PCV/PS	2 (25)		
A/C	2 (25)		
MV setting 48 hours after Modafinil			
FIO2			
Median (IQR)	0.30 (0.25-0.40)		
PEEP			
Median (IQR), cmH2O	8 (5-9)		
PaO2/ Fio2			
Median (IQR)	195 (170-390)		
MV mode (n, %)			
PCV	2 (25)		
PS	2 (25)		
PRVC	2 (25)		
Alternating PCV/PS	1 (12.5)		
A/C	0		
Duration of MV			
Median (IQR), days	17.5 (15-31.75)		
Tracheostomy (n, %)	5 (62.5)		
ICU length of stay			
Median (IQR) ,days	28.5 (20.25-48)		
Hospital length of stay			
Median (IQR) ,days	36.5 (26.75-115.25)		
28-days all-cause mortality (n, %)	2 (25)		

Clinical outcome	Value
90-days all-cause mortality (n, %)	5 (62.5)

Table Footnote

Abbreviation: AC: assist-control mode, FiO2: fraction of inspired oxygen, MV: mechanical ventilation,

PaO2: partial pressure of oxygen, PEEP: positive end-expiratory pressure, PCV: pressure control

ventilation, PS: pressure support, PRVC: pressure-regulated volume control